Otsuka Pharmaceutical
 | |
Native name | 大塚製薬株式会社 |
|---|---|
Romanized name | Ōtsuka Seiyaku Kabushiki-gaisha |
| Sector | Public KK |
| TYO: 4578 TOPIX 100 Component | |
| Industry | Pharmaceutical |
Number of locations | 69 |
Area served | Worldwide |
Key people | Tatsuo Higuchi (President) |
| ¥ 57.0 billion (2017) | |
| Owner | Nomura Trust and Banking investment trusts (11.43%) and investment trusts managed by other banks |
Number of employees | 5,634 (2017) |
| Parent | Otsuka Holdings Co. Ltd |
| Website | otsuka.com |
Otsuka Pharmaceutical Co., Ltd. (大塚製薬株式会社, Ōtsuka Seiyaku Kabushiki-gaisha) (TYO: 4578)は、日本の東京、大阪、鳴門に本社を置く製薬会社である。1964年8月10日に設立された。
History
OPC's parent company Otsuka Holdings Co. Ltd. joined the Tokyo Stock Exchange through an initial public offering (IPO) on December 15, 2010, at which time Otsuka Holdings was Japan's No.2 drug maker by sales after industry leader Takeda Pharmaceutical Company. The IPO debuted at $2.4 billion, making it the largest for a pharmaceutical company up to that time.
Otsuka Pharmaceutical Co. Ltd Holdings
In 1955, the company started a football club called "Otsuka Pharmaceutical SC." In 2005 the name changed to Tokushima Vortis. The club is based in Naruto.
In 1986, Otsuka Holdings Co. Ltd. acquired Ridge Vineyards.
In 1990, Otsuka Holdings Co. Ltd. acquired Crystal Geyser Water Company.
In 2008, Otsuka Pharmaceutical Co. acquired 49% of Alma S.A., which is the parent company of CG Roxane.
In early 2012, Otsuka announced it would focus its "future operations on CNS disorders and oncology". This decision necessitated a revision in the terms of an agreement with UCB to end collaboration on immunology products while continuing collaboration in the CNS area.
In September 2013, Otsuka Holdings it acquired Astex Pharmaceuticals for close to $900 million.
In December 2014, Otsuka Holdings struck a deal to buy Avanir Pharmaceuticals for $3.54 billion.
In March 2017, the company agreed to acquire Neurovance, Inc. for $250 million, gaining the firm’s Phase III-ready ADHD drug centanafadine (previously EB-1020). Otsuka's subsidiary Otsuka America will pay $100 million upfront for Neurovance, plus up-to $150 million in development and approval milestones. As a result of the transaction, Neurovance will operate as an indirect, wholly owned subsidiary.
In July 2017, the business acquired Daiya.
In July 2018, Otsuka agreed to acquire Visterra for $430 million cash and renal-focused ReCor Medical, Inc.
In August 2023, the company announced its intention to acquire Mindset Pharma Inc for up to CAD$80 million.
Acquisition history
- Otsuka Pharmaceutical Co., Ltd
- Ridge Vineyards (Acq 1986)
- Crystal Geyser Water Company (Acq 1990)
- Astex Pharmaceuticals (Merged 2011, Acq 2013)
- Astex Therapeutics Limited
- SuperGen, Inc
- Avanir Pharmaceuticals (Acq 2014)
- Daiya (Acq 2017)
- ReCor Medical, Inc. (Acq 2019)
- Otsuka America, Inc
- Visterra (Acq 2019)
- Neurovance, Inc (Acq 2017)
- Mindset Pharma Inc (Acq 2023)
Products
External links
- (in Japanese) Otsuka Pharmaceutical Company, Limited.
- (in English) Otsuka Integrated Report 2017 (PDF) (Archived 2021-05-25 at the Wayback Machine)
 | この記事は、クリエイティブ・コモンズ・表示・継承ライセンス3.0のもとで公表されたウィキペディアの項目Otsuka Pharmaceutical(28 October 2023編集記事参照)を素材として二次利用しています。 WB item:  |
- TOPIX 100
- Otsuka Pharmaceutical
- Companies listed on the Tokyo Stock Exchange
- Pharmaceutical companies of Japan
- Food and drink companies of Japan
- Pharmaceutical companies established in 1964
- Manufacturing companies based in Tokyo
- Japanese brands
- 2010 initial public offerings
- Multinational companies headquartered in Japan